Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: a prospective three-arm randomized clinical trial
ConclusionBased on the results, severe cases of COVID-19 treated with dexamethasone might have a better clinical status at 28-day follow-up compared to methylprednisolone and hydrocortisone at an equivalent dose. Larger multicenter trials are required to confirm our findings.
Source: Wiener Medizinische Wochenschrift - Category: General Medicine Source Type: research
More News: Clinical Trials | COVID-19 | Dexamethasone | General Medicine | Hydrocortisone | Intensive Care | International Medicine & Public Health | Methylprednisolone | Respiratory Medicine | Statistics | Study | WHO